CAPA follows up with another Letter outlining our concerns with the proposed PMPRB guidelines and overall pricing regime in Canada. As CAPA members, we think changes are needed to drug pricing policies, because we know that drug prices continuously going up are not...
Access to the right medicines is an important component in managing arthritis. In Canada, the Patented Medicines Prices Review Board (PMPRB) plays a key role in drug pricing in Canada. On July 1, 2020, the newly amended Patented Medicines Regulations will come into...
English 
Français du Canada